Clinical trials: Locally Advanced or Metastatic Solid Tumor
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT04842630
- Testing
- SHR-1916
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT06244992
- Testing
- PTT-936, Combination of PTT-936 and anti-PD-1/L1 therapy
- Where
- 6 sites in United States, China
- Volunteers
- 68 people
- Sponsor
- Pyrotech Therapeutics, Inc.
Unresectable Locally Advanced or Metastatic Cancer
First-in-Human Study of TAK-280 in Participants With Solid Tumors
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to…
- Trial name
- NCT05220098
- Testing
- TAK-280
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 69 people
- Sponsor
- Takeda
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Neoplasms
A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of vanucizumab as a single agent or in combination with atezolizumab in participants with locally advanced…
- Trial name
- NCT01688206
- Testing
- Atezolizumab [TECENTRIQ], Vanucizumab
- Where
- 14 sites in Belgium, France and 1 more
- Volunteers
- 132 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced or Metastatic Malignant Solid Tumors
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor.
- Trial name
- NCT07287995
- Testing
- ASP2998, Pembrolizumab, Enfortumab Vedotin
- Where
- 9 sites in United States, Japan
- Volunteers
- 428 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumor, Adult
A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors
This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.
- Trial name
- NCT05866692
- Testing
- TY-2699a
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- TYK Medicines, Inc
Advanced or Metastatic Solid Tumors
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid…
- Trial name
- NCT06752681
- Testing
- DAY301
- Where
- 11 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Day One Biopharmaceuticals, Inc.
Solid Tumor
Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors
HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the safety/tolerability、the pharmacokinetic profile and efficacy of HS-10365 in Chinese advanced solid tumor…
- Trial name
- NCT05207787
- Testing
- HS-10365
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.
- Trial name
- NCT03565991
- Testing
- Avelumab, Talazoparib
- Where
- 100 sites in United States, Belgium and 7 more
- Volunteers
- 202 people
- Sponsor
- Pfizer
NSCLC Stage IV
HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC
This is a Phase 1, open-label, multicenter, dose escalation study of HY1272 (administered via IV) evaluating both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in patients diagnosed with locally advanced or…
- Trial name
- NCT06218940
- Testing
- HY1272
- Volunteers
- 40 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Claudin 18.2, Solid Tumor Malignancies
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
This open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors that are positive for Claudin 18.2 and have progressed on…
- Trial name
- NCT07704866
- Testing
- FG-B901, FG-M108
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Locally Advanced, Recurrent or Metastatic Malignancies
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07022002
- Testing
- SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Cancer, Metastatic Solid Tumor
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in…
- Trial name
- NCT06548672
- Testing
- BC3195
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, multicenter, first-in-human, open-label, dose-escalation, and dose expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX35 administered as a single-agent…
- Trial name
- NCT05360381
- Testing
- HLX35
- Where
- 2 sites in China
- Volunteers
- 82 people
- Sponsor
- Shanghai Henlius Biotech
Solid Tumor
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
The main purpose of this Phase I study is to access the safety and tolerability of SHR-1701 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.
- Trial name
- NCT03710265
- Testing
- SHR-1701
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined…
- Trial name
- KontRASt-R (NCT07468071)
- Testing
- Opnurasib, TNO155, trametinib
- Where
- 21 sites in Belgium, Canada and 8 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic or Locally Advanced Solid Tumors
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally advanced solid tumors.
- Trial name
- NCT05028556
- Testing
- Cohort 1 of Y101D, Cohort 2 of Y101D, Cohort 3 of Y101D
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.